1 t in survival, more attention has focused on
postmastectomy breast reconstruction (PBR).
2 Purpose The goals of immediate
postmastectomy breast reconstruction are to minimize def
3 The only grade 4 toxicity of
postmastectomy chemotherapy was hematologic (10%).
4 RT) were postlumpectomy breast or (optional)
postmastectomy chest wall.
5 he tumor bed plus a 1-2-cm margin defined at
postmastectomy CT.
6 from randomized trials testing the value of
postmastectomy irradiation and a meta-analysis of 78 ran
7 She is referred for consideration of
postmastectomy irradiation.
8 ience high rates of LRR and may benefit from
postmastectomy irradiation.
9 Postmastectomy or regional radiotherapy was prohibited.
10 studies are needed to determine the value of
postmastectomy radiation for patients with stage II brea
11 New indications for
postmastectomy radiation have caused a dramatic increase
12 vement of pCR does not preclude the need for
postmastectomy radiation if warranted by the pretreatmen
13 rom postmastectomy radiation, but the use of
postmastectomy radiation in N0 patients is not supported
14 Randomized trials have demonstrated that
postmastectomy radiation reduces LRR, but no overall sur
15 has analyzed the changing patterns of use of
postmastectomy radiation therapy (PMRT) during the perio
16 Evolving data on the effectiveness of
postmastectomy radiation therapy (PMRT) have led to chan
17 Clinical trials indicate that
postmastectomy radiation therapy (PMRT) improves surviva
18 Purpose Conventionally fractionated
postmastectomy radiation therapy (PMRT) takes approximat
19 chemotherapy or hormonal therapy and without
postmastectomy radiation therapy (PMRT).
20 guiding decisions on who might benefit from
postmastectomy radiation therapy after upfront chemother
21 stablished which patients might benefit from
postmastectomy radiation therapy after upfront surgery,
22 ical trial data are needed to assess whether
postmastectomy radiation therapy can be safely omitted i
23 For CPS+EG scores >/=3, use of
postmastectomy radiation therapy decreases the likelihoo
24 %), mastectomy in 297 (17%) and mastectomy +
postmastectomy radiation therapy in 744 (44%).
25 and breast reconstruction, particularly when
postmastectomy radiation therapy is anticipated.
26 In summary,
postmastectomy radiation therapy moderately increases th
27 mastectomy alone, or mastectomy followed by
postmastectomy radiation therapy was recorded.
28 mor board recommended adjuvant chemotherapy,
postmastectomy radiation therapy, and endocrine therapy.
29 ars to be a function of the portals used for
postmastectomy radiation therapy, which do not expose th
30 nd can be used to tailor recommendations for
postmastectomy radiation therapy.
31 and > or =10 years, respectively, following
postmastectomy radiation therapy.
32 llary lymph node metastases may benefit from
postmastectomy radiation, but the use of postmastectomy
33 In patients undergoing
postmastectomy radiation, the use of autologous reconstr
34 Prior studies have found that
postmastectomy radiotherapy (PMRT) for breast cancer (BC
35 As the use of breast reconstruction and
postmastectomy radiotherapy (PMRT) has increased over th
36 linical Oncology guideline concerning use of
postmastectomy radiotherapy (PMRT).
37 isease-free and overall survival benefits of
postmastectomy radiotherapy for patients in particular p
38 r features having mastectomy if the need for
postmastectomy radiotherapy is clear with the finding of
39 Methods Women undergoing immediate
postmastectomy reconstruction for invasive cancer and/or
40 image gains continued to manifest at 2 years
postmastectomy reconstruction.
41 gh LRR rates in patients who did not receive
postmastectomy RT were lower in the AC+T arm, the differ